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Lung cancerAbstract Background: We aimed to evaluate the usefulness of multidetector row computed
tomography (MDCT), with angiography, as well as its generated virtual bronchoscopy (VB) in
the evaluation of patients with hemoptysis due to lung cancer.
Methods: A prospective study was carried out on 24 patients diagnosed as primary lung cancer
and presented with hemoptysis, from May 2011 to August 2014. They underwent MDCT using a
16-detector row scanner with bronchial and pulmonary angiographic techniques. MDCT-
generated VB was carried out and compared to ﬁndings obtained by ﬁberoptic bronchoscopy (FOB).
Results: MDCT identiﬁed the cause of hemoptysis and its angiography detected the site and vas-
cular source of bleeding in 96% of patients. Virtual bronchoscopy had sensitivity, speciﬁcity, and
accuracy of 91%, 50%, and 87.5%, respectively. While FOB detected 11, 19, 3 and 2 endoluminal
lesions, obstructive lesions, external compressions, and mucosal abnormalities; VB detected 7, 25,
11, and 0 lesions, respectively.rculosis.
280 S.A.A. Mohamed et al.Conclusion: MDCT angiography is a useful and non invasive method that allows a rapid and
detailed identiﬁcation of abnormal vasculature responsible for hemoptysis in patients with lung can-
cer. MDCT-generated virtual bronchoscopy is an accurate, and non invasive method for evaluating
obstructions, endoluminal masses, and external compressions in patients with hemoptysis due to
lung cancer.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hemoptysis is deﬁned as bleeding arising from the lower air-
ways [1]. Identifying the etiology of hemoptysis and classifying
it in terms of the amount of blood expectorated as well as the
rate of bleeding play a fundamental role in deﬁning the timing,
way and place of managing a patient with hemoptysis [2].
There are multiple causes of hemoptysis, including airway
diseases, parenchymal lung diseases, and thoracic malignancy
[3]. In the majority of cases, the source of massive hemoptysis
is the bronchial circulation. However, nonbronchial systemic
arteries can be also a signiﬁcant source [2]. Regardless of the
amount and etiology of hemoptysis, patients must be hospital-
ized immediately and must undergo urgent investigations
including imaging and ﬁberoptic bronchoscopy, FOB [4].
Because patients with malignant tumors of the thorax fre-
quently have complete bronchial obstructions caused by endo-
luminal tumors and extrinsic compression, a noninvasive,
reproducible, and objective method for sequentially evaluating
these abnormalities might prove useful in guiding therapy and
assessing treatment response in these individuals [5]. Patients
with hemoptysis due to suspected neoplastic lesion typically
undergo conventional CT scanning of the chest, followed by
FOB [4].
CT generates 2-D cross-sectional images of the thorax to
provide information regarding peribronchial anatomy. In the
evaluation of major endobronchial disease, CT scans have a
sensitivity of 63–100% and a speciﬁcity of 61–99% [6]. Subop-
timal scanning techniques, inappropriate slice thickness, and
artifacts between sections may limit the accuracy of airway
anatomy deﬁned by conventional CT scans. FOB remains
the best modality for evaluation of endoluminal and mucosal
lesions; however, endoscopy yields no information about the
extent of extraluminal disease or airway patency distal to a
high-grade stenosis [7]. In addition, FOB poses a potential risk
to the patient because of sedation; this risk may be increased in
patients with advanced intrathoracic disease [8].
Recently, the development of multidetector row CT
(MDCT) has provided a comprehensive, noninvasive method
of evaluating the entire thorax [1,9]. MDCT angiography
allows clear depiction of the origins and trajectories of abnor-
mally dilated bronchial or non-bronchial systemic arteries that
may be the source of hemorrhage requiring embolization [2].
Even more, physicians can now explore the tracheo-
bronchial tree on volumetric three-dimensional images with
the increasing sophistication in CT technology [10]. Virtual
bronchoscopy is a promising computer-assisted imaging tech-
nique that allows a three dimensional (3D) evaluation of the
tracheobronchial tree similar to those obtained during FOB.
Although the technique was described in the mid 1990s, it is
generating new interest as a result of improvements inmultidetector computed tomography and postprocessing tech-
nology [11]. It was found to be highly accurate in the detection
of central airway stenosis and staging of lung cancer [12].
Assiut University Hospital and South Egypt Cancer Insti-
tute (SECI) are tertiary referral centers, where many patients,
from all over Upper Egypt, are referred for the evaluation and
management of hemoptysis and lung cancer.
Therefore, in the current study, we had 2 main aims; ﬁrst is
to report our experience with the use of MDCT and its angio-
graphic technique in identifying the site of bleeding and its vas-
cular origin in patients with hemoptysis due to lung cancer.
Second, is to assess the diagnostic value of MDCT-generated
virtual bronchoscopy in patients with hemoptysis due to lung
cancer, in comparison to that of ﬁberoptic bronchoscopy, as
the gold standard tool for diagnosing those patients.
Patients and methods
Patients
This prospective study was carried out on 24 patients suffering
from hemoptysis, enrolled from May 2011 to August 2014.
These patients included those admitted to the Department of
Chest Diseases, Assiut University Hospital, with the diagnosis
of suspected LC, and those admitted to the Department of
Medical Oncology, South Egypt Cancer Institute (SECI), with
newly-diagnosed primary LC. The later received neither
chemotherapy nor radiotherapy. All patients were subjected
to complete clinical assessment. A detailed history was
obtained. Final diagnosis in patients with suspected LC was
established applying all clinical, laboratory, radiographic,
MDCT, bronchoscopic, and histopathologic ﬁndings.
The volume of hemoptysis corresponds to the cumulated
amount of bleeding, which was assessed from the onset of
bleeding until time of CT examination using a standardized
scale: spoonful (5 mL), small ﬁlled glass (100 mL), and
large ﬁlled glass (200 mL). According to the severity of hemo-
ptysis, it was classiﬁed as ‘‘mild” (<30 mL), ‘‘moderate”
(30–600 mL), ‘‘severe” or ‘‘massive” (>600 mL) [13].
Exclusion criteria included (1) pregnant females. (2)
Patients with chronic renal failure (or impairment) not on
regular dialysis. (3) Patients who are hemodynamically un-
stable. (4) Severe cardiac disease causing orthopnea. (5) Sensi-
tivity to the contrast medium. (6) Patients with life-threatening
hemoptysis till they become stabilized.
Full clinical examination was carried out. Laboratory data
were reviewed particularly for platelet count and coagulation
proﬁle.
All enrolled patients were subjected to (1) plain chest X-ray
(2) MDCT with angiography for assessment of the integrity of
pulmonary and/or systemic circulation. (3) MDCT-integrated
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histopathologic examination. Virtual bronchoscopy was done
24 h before FOB. The pulmonologist carried out FOB blindly
and independently from the results of VB. Findings obtained
by FOB were considered the ‘‘gold standard’’ for comparison
with those obtained by VB [14].
The study was approved by the local ethics committee and a
written consent was obtained from all patients who partici-
pated in the study.
Multidetector CT
Patient preparation
All patients were instructed to fast 6 h prior to the
examination. All steps of the study were explained in
detail for each patient. An IV access was secured (an 18 G
cannula).Scan protocol
A 16-detector row scanner General Electric (Light Speed Ultra
16; GE Medical Systems) was used. Pre and post contrast CT
studies were performed to all patients. CT imaging was per-
formed with patients in the supine position at maximal inspira-
tion during a single breath hold.
Acquisition
First, a scout view of the thorax is used to plan CT data acqui-
sition. A 28–33 cm ﬁeld of view, 512  512 matrix size, and a
collimation of 1.25 mm and 1.5–2 pitch were used. The mean
acquisition time was 12–18 s. By adjusting the exposure param-
eters, kilovoltage (100–140) and milliampere-seconds (90–140)
according to the patients weight the radiation dose to the
patient can be minimized without affecting the image quality.
The MDCT bronchial angiographic technique
CT imaging was acquired from the supraclavicular area to the
level of the ostia of the renal arteries, including the supraaortic
great vessels and the infra-diaphragmatic arteries, which may
also supply collateral branches to the lungs. Optimal enhance-
ment of both the pulmonary and systemic arteries was achieved
with the injection of 120 mL of a high-density, low osmolar
non-ionic contrast medium (350 mg/dL) with an automated
injector at a rate of 4 mL/s via an antecubital vein. The auto-
matic bolus triggering software program was also systemati-
cally applied, with a circular region of interest positioned at
the descending aorta at the level of carina, and as the threshold
value of 100 HU was approached, craniocaudal scanning
started. Thoracic CT angiography with a combination of
selected reformatted images is done. Assessment of the lung
parenchyma and airways as well as the mediastinum was
always done as in routine CT chest studies, using both lung par-
enchyma and mediastinal window settings.
Post processing techniques
Post-processing of the raw data was performed with axial thin
section images, multiplanar reformation (MPR), interactive
maximum intensity projection (MIP), and volume-rendered
(VR) techniques in order to optimally evaluate the origins
and courses of the bronchial and non-bronchial systemic arter-
ies (NBSAs).Data interpretation for routine CT chest
CT was analyzed to look for the cause of hemoptysis and to
localize the site of hemoptysis. Images were viewed in the lung
and mediastinal window to look for parenchymal changes, any
lymphadenopathy, pleural thickening, and major vessels.Analysis of bronchial arteries
CT interpretation was done by using axial images, multiplanar
reformation images, and 3-dimensional reconstruction (MIP
and VR) images to identify bronchial arteries, and the follow-
ing parameters were recorded:
(1) The total number of bronchial arteries per side; (2) the
site of the ostium of the bronchial artery (or arteries); (3) loca-
tion of the ostium on the wall of the descending aorta (ie, pos-
terior, medial, anterior, or lateral), and its position relative to
the tracheal carina, (4) bronchial artery diameter; (5) visualized
course of bronchial arteries.
Bronchial arteries were considered abnormal when (a) the
diameter of the bronchial artery wasP2 mm, or (b) the course
of the bronchial artery was visualized up to the hilum. The
bronchial artery that satisﬁed either or both of these criteria
was considered an abnormal hypertrophied artery and as a
source of hemoptysis.
The origin of bronchial artery was considered orthotopic
when the origin was from the descending aorta between the
levels of the T5 and T6 vertebrae and ectopic when identiﬁed
at a level of the descending aorta other than the expected ori-
gin (ie, outside levels T5–T6) or from any aortic branch vessel.
Analyses of non-bronchial systemic arteries
Arteries that enter the lung parenchyma through the inferior
pulmonary ligament or through the adherent pleura and with
trajectories that are not parallel to the bronchi are considered
as non-bronchial arteries. They were considered abnormal
when they become dilated and tortuous, and were seen within
extrapleural fat in association with pleural thickening
(P3 mm) and/or lung parenchyma abnormalities. Whenever
an abnormal nonbronchial systemic artery was identiﬁed, its
origin and course were noted.
Virtual bronchoscopy
During the VB examination, the tracheobronchial tree was
screened axially with 0.6 mm slices from the thoracic inlet to
the end of the diaphragm after administering intravenous con-
trast material. Axial CT, coronal and sagittal MPR images
with a slice thickness of 1 mm and with section intervals of
1 mm were reconstructed. Two-dimensional views were evalu-
ated at the standard parenchymal window (level 600, wide-
ness 1200) and mediastinal window (level 40, wideness 400)
for lesions’ endobronchial extensions, relations with neighbor-
ing structures and accompanying pathologies.
The tracheobronchial tree was investigated with an objec-
tive comparison between VB and FOB. Endoluminal, obstruc-
tive, and mucosal pathologies were deﬁned and grouped
according to Finkelstein and coworkers’ classiﬁcation [11] as
follows; endoluminal mass is deﬁned as a mass protruding into
the lumen with <50% occlusion, obstructive lesion is deﬁned
as bronchial narrowing of >50%, and mucosal lesion is
deﬁned by the presence of hemorrhage, erythema, or tissue
Table 1 Demographic data and histopathologic diagnosis of
the studied patients.
Parameter Patients No (percent)
Age (years)
Mean ± SD 54.20 ± 12.82
Range 33.0–78.0
Gender
Male 20 (83.3%)
Female 4 (16.7%)
Smoking history
Non-smokers 5 (21%)
Smokers 19 (79%)
Total pack/year (Mean ± SD) 78.1 ± 44.2
Grade of hemoptysis
Mild 7 (29%)
Moderate 17 (71%)
Lung cancer at presentation
Suspected 10 (42%)
Known 14 (58%)
Location of lung cancer
Central 22 (92%)
Peripheral 2 (8%)
Histopathologic diagnosis
Squamous cell carcinoma 16 (67%)
Adenocarcinoma 3 (13%)
Large cell carcinoma 2 (8%)
Small cell carcinoma 2 (8%)
Undiﬀerentiated carcinoma 1 (4%)
282 S.A.A. Mohamed et al.friability. Moreover, external compressions detected via VB
and MPR ﬁndings were recorded.
Fiberoptic bronchoscopy
Fiberoptic bronchoscopy was performed by a pulmonologist,
within 24 h after VB. Bronchoscopies were performed via the
oral or nasal route with a ﬂexible ﬁberoptic bronchoscope
(Pentax SB 15; Pentax, Japan) under local anesthesia (Lido-
caine HCl 10 mg/dose spray – midazolam 5 mg IV). Lesions
of the tracheobronchial tree were grouped as ‘endoluminal
lesions’ and ‘obstructive lesions’ as with VB. The presence of
mucosal lesions and external compression was also recorded.
During FOB, samples were obtained using biopsy forceps,
needle aspiration (A 13-mm 21-gauge cytology needle;
NA-2C-1; Olympus Corporation), brushing, bronchoalveolar
lavage or a few of them accordingly. A specialized pathologist
evaluated the materials. Final diagnoses were approved by
histopathological analysis of specimens obtained during
bronchoscopy.
Statistical analysis
Data were analyzed using the Statistical Product and Service
Solutions (Windows version 16.0; SPSS Inc. Chicago, USA).
FOB results were used as a reference for comparisonwith VB
results [11,14]. Qualitative results regarding the description of
tracheobronchial abnormalities with VB were deﬁned as true-
positive, true-negative, false-positive and false negative ﬁndings.
A true-positive ﬁnding was classiﬁed as an abnormality noted in
both image modalities (FOB and VB), whereas a true-negative
ﬁnding was deﬁned as an absence of airway abnormalities on
FOB and VB. A false-positive ﬁnding was deﬁned as a tracheo-
bronchial section noted as abnormal onVBbut normal onFOB.
A false-negative ﬁnding was deﬁned as a tracheobronchial sec-
tion that appeared normal on VB but abnormal on FOB. Sensi-
tivity, speciﬁcity, positive predictive value (PPV), negative
predictive value (NPV) and accuracy were calculated as follows:
sensitivity: true-positive/false-negative + true-positive; speci-
ﬁcity: true negative/false-positive + true-negative; PPV: true-
positive/true-positive + false-positive; NPV: true-negative/
true negative + false-negative; accuracy (%) = 100  (true-
positive + true-negative/true-positive + false-positive + true-
negative + false-negative).
Results
Twenty-four patients were prospectively enrolled into the cur-
rent study. They included 20 (83.3%) males and 4 (16.7%)
females with a mean age of 54 years (range from 33 to 78).
Nineteen out of 24 patients (79%) were cigarette smokers, with
a mean total pack/year of 78.1. Histopathologic diagnosis
revealed that 22 out of 24 patients (91.7%) had non-small cell
lung cancer (NSCLC), while 2/24 (8.3%) had small-cell lung
cancer (SCLC). Twenty-two out of 24 (92%) tumors were cen-
trally located, while 2/24 (8%) were peripherally located.
Table 1 shows these results. Plain chest X ray was considered
as successfully contributing in identiﬁcation of the cause of
hemoptysis in 17/24 (70%) patients.
MDCT identiﬁed the cause of hemoptysis in 23 out of 24
patients (96%). Those 23 patients included 20 (83.3%) patientswith lung parenchymal abnormalities and 3 (16.7%) patients
with isolated vascular abnormalities without parenchymal
abnormalities. All patients with lung parenchymal abnormali-
ties had associated vascular abnormalities (Fig. 1). In the
remaining 1 out of 24 patients of the study (4%), neither
parenchymal nor vascular abnormalities were detected as the
cause of hemoptysis. Table 2 shows details of these results.
MDCT angiography was able to detect the vascular source
of bleeding in 23/24 (96%) of the studied cohort. Bronchial
arteries were the major source of bleeding, being detected in
18 (75%) patients. Table 2 shows these vascular abnormalities
and their relation to parenchymal abnormalities. A total of 38
bronchial arteries was detected in 18 out of 24 (75%) patients
(13 right BAs, and 25 left BAs; 2 patients had double left-sided
BA) (Fig. 1). Twelve out of 38 detected BAs (31%) were seen
to be dilated (>2 mm) in 10 patients (5 right BAs and 7 left
BAs) (Table 3). Twenty-four out of 38 (63%) detected bron-
chial arteries were traceable to the level of pulmonary hila.
With regard to the ostia of bronchial arteries, our results
showed that 35/38 (92%) of the BAs seen were orthotopic,
while 3/38 (8%) were ectopic (Table 3). The latter was seen
in 3 patients, 1 was right-sided (from the aortic arch) and 2
were left-sided (from the lower part of descending thoracic
aorta).
Notably, the origins of orthotopic mediastinal BAs were
best depicted on overlapping axial thin-section images. Two-
dimensional MIP reformatted images in the coronal oblique
and sagittal planes readily depict the tortuous course of the
BAs from their origins (descending thoracic aorta) to the lungs
Figure 1 Female patient 65 years old, complaining of mild hemoptysis of 1 month duration. MDCT of the chest shows an irregular
thickened wall cavitary lesion in both mediastinal (A) and pulmonary (B) windows, in the posterior segment of the right lower lobe. Right
sided pleural effusion and subcutaneous nodule are also identiﬁed. Bronchoscopic biopsy revealed squamous cell carcinoma. A 3-D
volume rendering (C) showed enlarged right bronchial artery originating from the aorta and supplying the cavitary lesion.
Table 2 Source of bleeding detected by MDCT and its
relation to parenchymal abnormalities.
Source of
bleeding
No of
patients
(%)
With
parenchymal
abnormality No
(%)
Without
parenchymal
abnormality No
(%)
Bronchial
artery
18
(75%)
16 2
Non-
bronchial
systemic
artery
2 (8%) 2 0
Pulmonary
artery
3 (13%) 2 1
Not detected 1 (4%) 0 1
Table 3 Radiologic criteria of bronchial arteries depicted on
MDCT angiography.
Detected bronchial arteries
Orthotopic Ectopic
(35/38, 92%) (3/38, 8%)
Right (13)
Dilated 4 1
Non-dilated 8 0
Left (25)
Dilated 7 0
Non-dilated 16 2
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straight coronal planes were better suited for the analysis of
the intercostals and internal mammary arteries; and axial
reconstructed images were ideal for demonstrating the inferior
phrenic arteries and branches from the celiac axis.
Non-bronchial systemic source of bleeding was encoun-
tered in 2/24 (8%) patients (Table 2) in the form of dilated
intercostal vessels with pleural thickening (>3 mm) and in
association with parenchymal lung abnormalities in these 2
patients.
The pulmonary circulation contributed to hemoptysis in
3/24(13%) patients (Table 2).With regard to the results obtained by VB and FOB, our
data showed that, in 22 out of the 24 patients (92%), tracheo-
bronchial abnormalities were present on FOB, whereas 2
patients (8%) had normal ﬁndings on FOB. None of the
patients had ‘‘pure” tracheal abnormalities. In 20 of these 22
patients (91%), VB conﬁrmed the abnormality diagnosed by
FOB. Two patients (9%) with abnormalities on FOB had nor-
mal ﬁndings on VB. One patient had normal ﬁndings on both
VB and FOB. One patient with normal ﬁndings on FOB had
an abnormality according to VB (Fig. 2). Based on these num-
bers, sensitivity and speciﬁcity were calculated for VB as 91%
and 50%, respectively, whereas PPV and NPV were 95% and
33%, respectively. Accuracy was 87.5%.
The study group
n = 24
FOB positive
n = 22
FOB negative
n = 2  
VB positive
n = 20             
(true positive)
VB positive
n = 1            
(false positive)
VB negative
n = 1             
(true negative)
VB negative
n =2             
(false negative)
Figure 2 Diagnostic yields of virtual bronchoscopy (VB) and
ﬁberoptic bronchoscopy (FOB).
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ﬁndings, FOB had a sensitivity of 100% and speciﬁcity of
50%, PPV of 95.6% and NPV of 100%.
With regard to the numbers and types of lesions detected by
VB and FOB, our results showed that; while FOB detected 11
endoluminal lesions, VB detected 7. While FOB detected 19
obstructive lesions, VB detected 25. (Table 4, Figs. 3 and 4).
In evaluating external compression, FOB detected 3 lesions
and VB detected 11. For the mucosal pathologies, while VB
did not provide any information, FOB detected 2 mucosal
pathologies. (Table 4).
Discussion
The current prospective study aimed to evaluate the role of
MDCT with bronchial and pulmonary angiography, as well
as virtual bronchoscopy, in the evaluation of hemoptysis due
to lung cancer among 24 patients, enrolled through a 3-year
period, in Upper Egypt. To the best of our knowledge, this
is the ﬁrst study reporting the utility of MDCT angiography,
and VB in evaluating hemoptysis due to lung cancer, in Upper
Egypt.
Primary lung cancers account for 23% of cases of hemopt-
ysis in the United States. Bronchogenic carcinoma is a com-
mon lung cancer responsible for hemoptysis in 5–44 percent
of all cases [15]. In concordance with these reports, in our
results, all patients had the diagnosis of bronchogenic carci-
noma, and as 92% of the these tumors were centrally located,
hemoptysis is an anticipated presentation in our cohort.
Bleeding from malignant or benign tumors can be sec-
ondary to superﬁcial mucosal invasion, erosion into blood ves-
sels, or highly vascular lesions. Breast, renal, and colon cancersTable 4 Number of lesions detected by virtual bronchoscopy
and ﬁberoptic bronchoscopy*.
FOB VB
Endoluminal lesion 11 7
Obstructive lesion 19 25
External compression 3 11
Mucosal ﬁndings 2 0
* FOB; ﬁberoptic bronchoscopy, VB; virtual bronchoscopy.have a predilection for lung metastasis; however, metastatic
lung carcinoma rarely results in bleeding [11]. Obstructive
lesions may cause a secondary infection, resulting in
hemoptysis.
Imaging modalities used in the evaluation of hemoptysis
include chest radiography, computed tomography, and bron-
chial arteriography. More recently, the development of multi-
detector row CT (MDCT) has provided a comprehensive,
noninvasive method of evaluating the entire thorax [9]. One
more advantage of MDCT is the use of MDCT angiography
(MDCTA), which provides a detailed depiction of bronchial
and non bronchial systemic arteries, which is very important
in planning further management, including embolization pro-
cedures [16].
Our data revealed that, MDCT identiﬁed the cause of
hemoptysis in 23 out of 24 patients (96%). These results are
in agreement to those reported by Khalil et al., 90.5% [17].
Moreover, our data showed that MDCT angiography was able
to detect the vascular source of bleeding in 23/24 (96%) of
patients. Bronchial arteries were the major source of bleeding,
being detected in 18/24 (75%) patients. A total of 38 bronchial
arteries were detected in 18 out of 24 (75%) patients. Thirty-
one percent of the detected BAs were seen to be dilated.
Our ﬁndings are in agreement with those of previous
reports that showed that the source of bleeding, particularly
in severe hemoptysis, originates from the bronchial and pul-
monary arteries in 90% and 5% of cases, respectively [2,10].
In the remaining 5% of cases, hemoptysis may derive from
non bronchial systemic arteries. In addition, MDCTA revealed
that the non-bronchial systemic and pulmonary circulations
contributed to hemoptysis in 8% and 13% of patients,
respectively.
One of the major causes of recurrent hemoptysis after suc-
cessful embolization of bronchial arteries is the presence of
abnormal nonbronchial systemic arteries. So, it is important
to identify these abnormal nonbronchial systemic arteries
before embolization.
To report our experience with the use of VB and its utility
in hemoptysis due to LC, VB was carried out and its results
were compared to those of the FOB.
Virtual bronchoscopy (VB), also referred to as computer-
ized tomographic bronchography, is a technique that makes
use of 3-dimensional (3-D) reconstruction of high-resolution
helical CT images for noninvasive evaluation of the tracheo-
bronchial tree [10]. The basics behind using these high-
resolution CT techniques, is that VB exploits the natural
contrast between the air in the tracheobronchial tree and the
soft tissue of the airway wall to establish a plane for generating
the virtual airway; so the images are used to generate a 3-D
model of airway anatomy. Once the virtual airway is created,
the viewer can navigate through the airway in a 3-D manner
analogous to standard FB [10,11]. In addition, VB allows for
unconventional images, such as retrograde views of endolumi-
nal and extraluminal anatomy. The airway can be manipulated
in space and evaluated from multiple angles.
Evaluation of patients with hemoptysis due to suspected
lung cancer include the use of plain radiology, conventional
CT (better to use the MDCT if available), and FOB. In addi-
tion, MDCT can be used with angiography (MDCTA) and to
generate VB.
In most studies evaluation of the airways, FOB was used as
the reference ‘gold standard’ for comparison between FOB and
Figure 3 A male patient, 52 years old, presented with moderate haemoptysis for 2 weeks. MDCT of the chest; axial CT image (A) shows
a large well deﬁned irregular left hilar mass abutting the descending thoracic aorta. A distal consolidation patch is noted. Coronal
reformatting using minimum intensity projection (B) showing subtotal occlusion of the left lower lobe bronchus with patent distal
bronchioles. An endoluminal lesion (white arrows) obstructing the superior segment of the left lower lobe is seen at both virtual
bronchoscopy (C) and ﬁberoptic bronchoscopy (D). Bronchoscopic biopsy revealed squamous cell carcinoma.
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‘gold standard reference ’for comparing the results of VB.
Therefore, the pulmonologist who performed the FOB was
blinded to the results of the VB.
Our results revealed that VB had sensitivity, speciﬁcity, and
accuracy of 91%, 50%, and 87.5%, respectively. These ﬁnd-
ings are in agreement to those reported in the literature
[10,11,14,18].
Finkelstein and coworkers [11] examined 32 patients with
thoracic malignant tumors via VB and compared the results
with those of FOB. They observed that 13/20 (65%) patients
had a total of 22 abnormal ﬁndings on FOB. VB detected
18/22 abnormal FOB as follows; 13 of 13 obstructive lesions,
5 of 6 endoluminal lesions, and 0 of 3 mucosal lesions. The sen-
sitivity of VB was 100% for obstructive lesions, 83% for endo-
luminal lesions, 0% for mucosal lesions, and 82% for all
abnormalities; and the speciﬁcity of virtual bronchoscopy
was 100% [11].
In an Egyptian experience, Sharaf El Din et al. [12] assessed
the roles of VB and FOB in staging LC. Twenty patients with
primary LC were evaluated. Seventeen cases with central
tumors were detected by both FOB and VB. They observed
that, broadening of the main carina was reported in 5 cases
by FOB and in 2 cases by VB, narrowing of lobar and segmen-
tal bronchi was reported in 7 cases by both VB and FOB.
Whereas FOB reported vocal cord lesions in 4 cases, tracheo-
bronchial mucous membrane lesions in 9 cases, broadening ofinterlobar and intersegmental carina in 4 cases; VB supple-
mented by HRCT detected peripheral tumors, lymphadenopa-
thy, lung parenchyma lesions, pleural effusion, and bony
deposits [12].
With regard to the numbers and types of lesions detected by
VB and FOB, our results showed that; while FOB detected 11
endoluminal lesions, VB detected 7. While FOB detected 19
obstructive lesions, VB detected 25. In evaluating external
compression, FOB detected 3 lesions and VB detected 11.
For the mucosal pathologies, while VB did not provide any
information, FOB detected 2 mucosal pathologies (Table 4).
Virtual bronchoscopy detected endoluminal lesions as
effectively as FOB, except for 4 locations in 2 patients. In
the retrospective assessment of these 2 patients detected by
FOB but not by VB, the result of VB did not change and
the difference was thought to be due to the size of the lesions.
Our data showed that VB detected obstructive lesions as
effectively as FOB. This agrees with previous data [11,14] VB
can be performed in regions distal to stenoses, where FOB
was not possible. Because of this advantage, it is thought that
VB might be used to complement FOB in selected cases. In the
literature, VB was found to be superior to FOB in the evalua-
tion of regions beyond stenoses and in grading stenoses [19].
FOB cannot show the situation in regions distal to severe
stenoses or total occlusion, the extension of the tumor, or
whether a collapse has occurred or not. Virtual bronchoscopy,
on the other hand, may be used to assess the bronchus distal to
Figure 4 A male patient, 53 years old, presented with attacks of haemoptysis. MDCT of the chest; axial CT image (A) shows multiple
pretracheal and subcarinal lymphadenopathy. A large right sided ill deﬁned mass encasing and attenuating the inferior branch of the right
main pulmonary artery as well as the bronchus intermedius is seen. Coronal reformatting (B) showing attenuated distal right bronchus
intermedius and lower lobe bronchus with complete obstruction of the middle bronchus. Virtual bronchoscopy image (C); complete
occlusion of the middle lobe bronchus and attenuated bronchioles of the lower lobe bronchus. FOB image (D) shows a mass completely
obstructing the middle lobe bronchus associated with circumferential narrowing of subsegments of the lower lobe bronchus.
Bronchoscopy guided biopsy revealed undifferentiated carcinoma.
286 S.A.A. Mohamed et al.the stenoses, the length of the stenoses and their positional
location [18,19]. These details are important for endobronchial
procedures such as laser therapy, stent placement and trans-
bronchial radiotherapy [10,11].
While FOB is difﬁcult to use in evaluating external com-
pressions, VB with the help of MPR may provide comprehen-
sive information. In the current study, while FOB detected 3
external compressions, VB detected 11. Adali et al. [14], in
their study of 22 patients, reported that FOB detected 2 exter-
nal compressions, while VB detected 15.
Via muliplanar images, VB allows quantitative measure-
ments like the size of a lesion, its relationship with neighboring
structures, the length of a stenosis and the diameter of a
bronchus. Therefore, in the evaluation of patients for surgery,
in contrast to FOB, VB and MPR should be considered
together [10].
For mucosal pathologies, our data showed that only 2
lesions could be detected by FOB while VB could not detect
any mucosal abnormalities. The low number of these mucosal
lesions in the present study can be explained by the fact that
14/24 (58%) of our cohort had known LC. Our data, again,are in agreement with those studies that reported a 0% sensi-
tivity of VB in detecting mucosal pathologies [11,14].
Every procedure has advantages and disadvantages. FOB
allows the direct evaluation of endoluminal and mucosal
lesions and can guide biopsies for histological analysis. It also
provides better assessment of mild degrees of stenosis. How-
ever, FOB has some limitations. It cannot pass through
severely narrowed airways. It provides scarce information con-
cerning the extent of extraluminal disease and it cannot be tol-
erated by some patients [10,20]. Virtual bronchoscopy is
particularly useful for orientation within the tracheobronchial
tree, and permits differentiation between intraluminal lesion
and extraluminal airway compression. Virtual bronchoscopy
allows one to assess the distal lesions and see beyond a steno-
sis. It may be able to distinguish between high-grade stenosis
and complete occlusion [11,18,19].
Virtual bronchoscopy has some disadvantages, namely it
cannot be used to evaluate mucosal details (eg. fragility, color
changes, vascularity), to show mucosal or submucosal
extensions, or to perform a biopsy, and also this method
cannot be used to depict functional stenoses due to
MDCT and VB in hemoptysis due to lung cancer 287tracheobronchomalasia [21]. The other limitation of VB was
that it cannot be used to obtain a histological diagnosis (mucus
plug, foreign body, embolism, benign mass and carcinoma)
[18]. Despite these disadvantages, improved resolution and a
probable increase in diagnostic abilities are expected to occur
due to technological developments [10].
It is thought that we should look to FOB and VB as com-
plementary, rather than competing methods, for evaluating
patients with tracheobronchial abnormalities, particularly
those with suspected LC [12,14], and we think that VB will
never completely replace FOB for the evaluation of such
patients. While FOB provides visualization and pathological
specimens, VB provides only visualization with a wider scope
than FOB.
The current study has some limitations. First, we have used
a 16-detector row MDCT device, Morita et al. [22] demon-
strated that 64 slice CT scanners showed the bronchial artery
anatomy better than 16 slice scanners. Second, is the relative
low number of enrolled patients. To conﬁrm our results, a lar-
ger or multi-center study is warranted.
Conclusion
Our data conﬁrm that MDCT angiography is a useful and non
invasive method that allows a rapid and detailed identiﬁcation
of abnormal vasculature responsible for hemoptysis in patients
with lung cancer. Moreover, MDCT-generated virtual bron-
choscopy is an accurate, valuable and non invasive method
for evaluating obstructions, endoluminal masses, and external
compressions in patients with hemoptysis due to lung cancer.
Virtual bronchoscopy and FOB are complementary tools for
evaluating those patients.
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